Pharmacological prevention of post-ERCP pancreatitis--an everlasting dream?
Hellmig
S
S
Department of General Internal Medicine, University Hospital of Schleswig-Holstein, Schittenhelmstr. 12, 24105 Kiel, Germany. s.hellmig@mucosa.de
Fölsch
U R
UR
D002760:Cholangiopancreatography, Endoscopic Retrograde / Q000009:adverse effects*; D003362:Cost-Benefit Analysis; D016670:Gabexate / Q000191:economics* / Q000627:therapeutic use*; D006801:Humans; D034321:Hyperamylasemia / Q000517:prevention & control; D010195:Pancreatitis / Q000209:etiology / Q000517:prevention & control*; D012017:Referral and Consultation; D015842:Serine Proteinase Inhibitors / Q000191:economics* / Q000627:therapeutic use*
D015842:Serine Proteinase Inhibitors; D016670:Gabexate